【摘要】 基于纳米脂质体良好的生物相容性、表面可修饰性、选择性和靶向性等特征，将放射性核素与纳米脂质体相结合，可实现降低放射性药物的不良反应、提高其治疗效率和靶向浓度的目的。近年来在核医学和核药学领域，越来越多的纳米核药开展了临床研究，展示出了良好的发展前景。针对放射性核素标记的纳米脂质体，在标记方法、靶向性、临床应用等方面的研究进展及其应用前景进行了分析和展望，旨在为肿瘤的靶向诊疗提供新的可能性。更多还原

【Abstract】 Based on the characteristics of nanoliposome, such as good biocompatibility, surface modifiability, selectivity and targeting, etc., the combination of radionuclide and nanoliposome can accomplish the objective of reducing adverse reaction of radiopharmaceutical, increasing the therapeutic efficiency and targeted concentration. Recently in the field of nuclear medicine and nuclear pharmacy, more and more nuclear nanomedicines have been applied in the clinical researches, showing good development prospects. For the radiolabeled nanoliposome, the research progress of labeling methods, targeting, clinical application, etc., and future application prospects are analyzed and reviewed, aiming to provide a new possibility for the targeted diagnosis and treatment of tumors.更多还原